References
- The Writing Group on behalf of the Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT. Climacteric 2009;12:368–377
- van der Schouw YT. Incidence and mortality of cardiovascular disease in postmenopausal women world-wide and relevance for preventive strategies. Climacteric 2009;12(Suppl 1):1–5
- Hu G, Jousilahti P, Qiao Q, Peltonen M, Katoh S, Tuomilehto J. The gender-specific impact of diabetes mellitus and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol 2005;45:1413–1418
- Pasternak R, Abrams J, Greenland P, Smaha L, Wilson P, Houston-Miller N. Task force #1 – identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003;41:1863–1874
- Mizuno K, Nakaya N, Ohashi Y, et al Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 2008;117:494–502
- Mora S, Glynn R, Hsia J, MacFadyen J, Genest J, Ridker P. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Results from the Justification for the use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–1077
- Boudreau D, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603–621